Reuters logo
BRIEF-Flexion Therapeutics says Zilretta demonstrated meaningful pain relief, functional improvement
April 28, 2017 / 1:05 PM / 7 months ago

BRIEF-Flexion Therapeutics says Zilretta demonstrated meaningful pain relief, functional improvement

April 28 (Reuters) - Flexion Therapeutics Inc

* Flexion Therapeutics - in analysis of pooled phase 2/3 data, Zilretta (FX006) demonstrated clinically meaningful pain relief, unctional improvement

* Flexion - separate phase 2 study shows prolonged synovial localization, diminished systemic exposure of corticosteroid with zilretta versus. steroid injections

* Flexion Therapeutics Inc - authors examined improvements in pain and function using pooled data from three phase 2 and 3 randomized trials

* Flexion Therapeutics - pooled data from 3 phase 2, 3 randomized trials individually demonstrated statistically significant reductions in weekly mean scores of ADP Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below